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ABSTRACT A j opioid binding protein (OBP), previously
purified to homogeneity from bovine striatal membranes, was
examined by immunoblotting with six antisera against bovine
rhodopsin. An antibody against the carboxyl-terminal tail of
rhodopsin and one against membrane-associated rhodopsin
gave strong signals at the appropriate molecular mass (65 kDa).
An antibody directed against the first cytoplasmic loop of
rhodopsin was weakly reactive. Three other antibodies did not
recognize OBP. This pattern of crossreactivity was identical to
that previously seen with j8-adrenergic receptors. The existence
of domains in the OBP, which are antigenically similar to those
in two other guanine nucleotide regulatory protein-coupled
receptors, supports the hypothesis that 1L opioid receptors have
the structure characteristic of this receptor family.
Members of a large family of receptors for hormones, neu-
rotransmitters, and peptides effect their signal transmission
by activating one of the guanine nucleotide regulatory pro-
teins (G proteins). This class of receptors includes the visual
opsins; a- and j8-adrenergic, muscarinic, dopamine, sub-
stance P, and substance K receptors; and many others (1-3).
Rhodopsins, the proteins most abundant and most easily
purified, have served as prototypes for structural studies of
this class of receptors. The primary amino acid sequences of
a number of receptor proteins of this family have been
determined by cloning cDNA or genomic DNA (4-8). Anal-
ysis of structural domains derived from the amino acid
sequence has revealed some significant features common to
all members of this family cloned to date. The most striking
feature is that all contain seven hydrophobic sequences that
are putative membrane-spanning helices and have been
proven to be so for bacteriorhodopsin (9). Homology in these
segments is particularly high among G-protein-coupled re-
ceptors. These domains are now known to form the ligand
binding site, which is similar for different receptors of this
family but different in details that provide ligand specificity
(10, 11). The cytoplasmic portions of the proteins, especially
the third loop and portions ofthe C-terminal tail, seem to play
a role in the coupling to G proteins (1-3, 12). These areas do
not seem to exhibit extensive linear sequence homology but
are thought to resemble each other in secondary and tertiary
structure and charge distribution (13, 14). It has previously
been reported (13) that antibodies against sequences in these
cytoplasmic regions of rhodopsin crossreact with /3-adrener-
gic receptor purified from mouse S49 lymphoma cells.
Biochemical and physiological evidence indicates that all
three major types of opioid receptors-,p, 8, and K-nega-
tively modulate adenylate cyclase and are therefore coupled
to G proteins (15-17). Thus, binding of opioid agonists to
these receptors results in inhibition of adenylate cyclase via
a protein sensitive to pertussis toxin, a characteristic of G.
and Go proteins (18, 19). Inhibition is reversed by the
antagonist naloxone. It has also been shown that in cultures
ofneuroblastoma-glioma hybrid cells aG protein, most likely
Go, mediates enkephalin-induced inhibition of Ca2+ current
(20).
In the present study, we have investigated the interaction
of a purified A opioid binding protein (OBP) isolated from
bovine striatal membranes with various antibodies generated
against both membrane-associated rhodopsin and specific
amino acid sequences contained in rhodopsin. Our results
provide evidence that, as shown previously with the f-ad-
renergic receptor, the purified 1L OBP contains sufficient
structural similarity to cytoplasmic regions of rhodopsin to
allow crossreactivity with specific antibodies to occur. These
particular regions of this family of receptors have been
demonstrated to be involved in interaction with and activa-
tion of G proteins and to provide sites for phosphorylation of
the receptors.
MATERIALS AND METHODS
Materials. Chemicals used in electrophoresis and immu-
noblotting were purchased from Bio-Rad. The second anti-
body used in immunoblotting was goat anti-rabbit IgG con-
jugated to alkaline phosphatase (Bio-Rad) at a 1:1000 dilu-
tion. Pansorbin cells used in immunoprecipitation were
purchased from Calbiochem.
Rhodopsin Antibodies. Rhodopsin antibodies were pre-
pared and characterized as described (13).
Peptide Antibodies. Peptides were isolated and sequenced
from purified OBP in collaboration with C. D. Strader
(Merck Sharp & Dohme) according to methods described for
the /3-adrenergic receptor (4). Briefly, this involved chemical
cleavage with CNBr to generate peptides since the N termi-
nus ofthe protein was blocked. After cleavage, peptides were
reisolated by reverse-phase HPLC. Rabbit polyclonal anti-
bodies were generated against peptide sequences and conju-
gated to thyroglobulin by either benzidine or glutaraldehyde.
Immunoblots and Immunoprecipitation. OBP was purified
according to Gioannini et al. (21) using CH-Sepharose-4B
coupled to 6-f3-naltrexylethylenediamine, followed by inter-
action of the partially purified protein (3000- to 5000-fold)
with wheat germ agglutinin-agarose. Samples were concen-
trated using Centricon-10 (Amicon). For electrophoresis,
samples containing 30-50 ng of purified OBP were diluted 1:1
in 2x PAGE sample buffer, incubated at 370C for 1 hr, and
Abbreviations: G protein, guanine nucleotide regulatory protein;
OBP, opioid binding protein.
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then submitted to electrophoresis through a 4.5% stacking gel
and a 10% running gel. The protein was transferred to
nitrocellulose (250 mA; 1.5 hr) in the presence of 0.1% SDS.
Nonspecific sites on the nitrocellulose were blocked with 3%
bovine serum albumin in phosphate-buffered saline. Samples
were incubated with antisera (1:100) overnight at 40C. In
blocking experiments, antisera were incubated with peptide
(100 or 200 AM) for 2 hr at 250C before they were incubated
with the nitrocellulose strip containing transferred OBP.
Peptides A-32 and 0-15 were kindly made available by Anatol
Arendt (University of Florida). A-32 (rhodopsin amino acid
sequence 324-348) is a peptide containing the amino acid
sequence 325-343 against which the rhodopsin antibody
directed against a portion of the C-terminal tail (CT1) was
prepared. 0-15 (amino acids 331-348) represents a rhodopsin
peptide, which lacks the first 6 amino acids of the CT1
peptide. The nitrocellulose was washed and treated with goat
anti-rabbit IgG conjugated to alkaline phosphatase (1 hr;
250C). Blots were washed and exposed to color reagent,
washed with distilled water, and dried. For each blot, stan-
dard markers (rainbow markers; Amersham) were also run.
Immunoprecipitations were carried out with purified OBP
that had been denatured by heating in 2% SDS. The sample
was then treated with 5% Nonidet P-40 and diluted 2.5-fold
in phosphate-buffered saline (pH 7.4) containing 0.1% bovine
serum albumin. Antiserum or normal rabbit serum (control)
was added to a final dilution of 1:100. Samples were incu-
bated overnight at 4°C. Antigen-antibody complexes were
precipitated by incubation with Pansorbin (Calbiochem) for
20 min at 4°C. Samples were centrifuged and supernatant was
aspirated. Pellets were dissolved in SDS/PAGE buffer, run
on 10% polyacrylamide gels, transferred to nitrocellulose,
and treated with antibodies; then the color was developed.
Aliquots of supernatants from the immunoprecipitations
were immunoblotted in the same manner.
RESULTS
We have reported the purification to homogeneity of an
active OBP from a digitonin extract of bovine striatal mem-
branes by using a combination of ligand and lectin affinity
chromatography (21). This protein binds opioid antagonists
specifically, reversibly, and with high affinity and a capacity
(Bmax) of 13,000 pmol per mg of protein. This is close to the
theoretical value for a pure protein of this size (65 kDa)
containing a single binding site. Considerable evidence has
been accumulated indicating that this binding protein is
derived from , opioid receptors. Under reducing conditions,
OBP migrates on SDS/PAGE to an apparent mass of 65 kDa.
This is the size we reported for , opioid receptors from
bovine striatal membranes crosslinked to human 125I-labeled
13-endorphin (22, 23).
Fragmentation of this N-terminal-blocked purified OBP
and sequencing of reisolated peptides have provided the
sequences of two peptides. The amino acid sequences of the
two peptides exhibit no homology to sequences in any data
base of known protein structures. Polyclonal antibodies to
portions of these peptides have been prepared (a preliminary
report has appeared; see ref. 24). These antisera immuno-
precipitate up to 65% of 1251-labeled OBP and produce a band
at 65 kDa in immunoblots of this protein.
To characterize further the nature of purified OBP, we
carried out experiments with polyclonal antisera prepared
against bovine rhodopsin or amino acid sequences present in
the rhodopsin structure, some of which had previously been
shown to crossreact with 83-adrenergic receptors purified
from mouse S49 lymphoma cells (13). The interaction of the
following antibodies with purified OBP was examined: (i) an
antibody generated against membrane-associated rhodopsin;
(ii) antibodies against amino acid sequences in the three
cytoplasmic loops, L1_2, L3-4, and L5-6; (iii) an antibody
against a region of the C terminus corresponding to amino
acids 325-343 (CT1); and (iv) an antibody against a segment
in the second extracellular loop.
Immunoblots using rhodopsin antisera were carried out
with batches of purified OBP, all ofwhich had been shown to
be immunoprecipitated by and to give positive immunoblots
with the antisera generated against the peptides sequenced
from purified OBP. Positive responses-i.e., bands at 65
kDa-were observed with three of the rhodopsin antisera at
a 1:100 dilution (Fig. 1). The strongest signal resulted from
interaction with the antibodies generated against CT1, the
peptide found in the carboxyl tail. A strong signal was also
detected with antibodies against membrane-associated
rhodopsin, for which the epitope is unknown. Finally, a weak
but detectable signal was observed with antibodies against
the first cytoplasmic loop between the first and second
membrane-spanning domains (data not shown). No signal
was detected with antibodies against sequences from other
cytoplasmic loops or against a sequence from an extracellular
loop (antiserum against cytoplasmic loop L34 is the only
negative blot shown). These results are identical to those
previously obtained in studies of the crossreactivity of these
antisera with f-adrenergic receptors (13).
The signal of the immunoblot of OBP with CT1 can be
almost completely eliminated by preincubation of the anti-
serum with a rhodopsin peptide, A-32 (rhodopsin amino acid
sequence 324-348), that contains the amino acid sequence
325-343 against which CT1 was generated (Fig. 2, lane 3). A
peptide, 0-15 (amino acids 331-348), that lacks the first 6
amino acids of the CT1 sequence produced no effect on the
immunoblot (lane 2).
To establish that the protein recognized by antibodies
against rhodopsin is the same as that recognized by antibod-
ies against OBP-derived peptides, the following experiments
were performed. OBP was immunoprecipitated by treatment
with antiserum against OBP-derived peptide followed by
protein A. A control sample in which antiserum was replaced
by normal rabbit serum was also carried through the proce-
dure. Immunoblots done on the supernatant gave barely
detectable bands at 65 kDa, whereas strong bands were
observed with the supernatants from samples "mock-
immunoprecipitated" with normal rabbit serum. These re-
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FIG. 1. Immunoblots of purified OBP with anti-rhodopsin anti-
bodies. Immunoblots were prepared as described at a dilution of
1:100. Lanes: 1, an antiserum (Ab 165), generated against a sequence
derived from purified OBP (positive control); 2, antibody against
sequence in the C-terminal tail of rhodopsin (CT1); 3, antibody
against membrane-associated rhodopsin; 4, antibody against se-
quence in cytoplasmic loop 2 between transmembrane domains 3 and
4 (L3-4)-
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FIG. 2. Blocking of signal from immunoblot of rhodopsin anti-
serum CT1 against purified OBP by rhodopsin peptide A-32. Immu-
noblots of antiserum CT1 against purified OBP were prepared as
described, at an antiserum dilution of 1:100. Lanes: 1, CT1; 2, CT,
+ 200AM peptide 0-15 (rhodopsin amino acid sequence 331-348); 3,
CT1 + 200 sM peptide A-32 (rhodopsin amino acid sequence
324-348); 4, Ab 165 against peptide from OBP (positive control).
sults indicate that immunoprecipitation with OBP-specific
antibodies depletes rhodopsin antibody-reactive material
from the supernatant. Moreover, positive immunoblots at 65
kDa were obtained with the immunoprecipitated pellet after
dissolving it in SDS/PAGE sample buffer to dissociate the
antigen-antibody complex, but not with the normal rabbit
serum control.
DISCUSSION
Limited proteolysis, site-directed and deletion mutagenesis,
and construction ofchimeric receptors with various members
of the G-linked protein family have been used to investigate
the role of the cytoplasmic regions of these G-linked receptor
proteins (10, 14, 25-27). Cytoplasmic domains of this recep-
tor protein family are involved with either binding or activa-
tion ofG proteins or recognition ofthese receptors by kinases
that specifically phosphorylate the ligand-activated forms.
These are processes common to all known receptors of this
family. It was shown in a previous report by two of us (28)
that the CT1 antibody interacts with a region involved in
G-protein (transducin) activation by rhodopsin. CT1 antibody
was able to reduce the rhodopsin-catalyzed transducin acti-
vation in a concentration-dependent manner. In addition, the
binding of transducin to rhodopsin competed with the binding
of the antibody.
The interaction of OBP purified from bovine striatal mem-
branes with a series of antibodies generated against either
membrane-associated rhodopsin or amino acid sequences
derived from rhodopsin gave the same pattern of crossreac-
tivity as that previously observed with B3-adrenergic recep-
tors purified from S49 lymphoma cells (13). Those antibodies
that gave strong, weak, or no reaction in immunoblots of
13-adrenergic receptor reacted identically in blots of OBP.
The signal from immunoblots with antibody CT1 was elimi-
nated by pretreatment of the antiserum with a peptide con-
taining the appropriate rhodopsin sequence but not with a
peptide lacking the 6 N-terminal amino acids of this se-
quence, supporting the specificity of the crossreactivity. It is
evident that antigenically similar structural domains within
the cytoplasmic region(s) exist in all three of these proteins.
The presence of common antigenic sites in such different
proteins suggests that these cytoplasmic regions may have
common structural and perhaps functional features and we
postulate that it reflects the probability (known to be true for
rhodopsin and the ,B-adrenergic receptor) that all three re-
ceptors belong to the receptor family coupled to G proteins.
Similar findings with a protein derived from NG108-15
cells, a source of 8 opioid receptors, have been obtained by
D. L. Newton, W. A. Klee, P. A. Hargrave, and G. Adamus
(personal communication). They found that an antibody
against a sequence immediately following the last transmem-
brane region in the carboxyl tail of rhodopsin can immuno-
precipitate a protein that had been labeled with the 8-selec-
tive affinity ligand, 3H-cis(+)-3-methylfentamylisothiocy-
anate. These results suggest that 8 receptors also share
antigenic sites with rhodopsin.
In a previous report (13), it was found that 3 amino
acids-lysine, asparagine, and proline (residues 325-327)-
seem to be involved in the interaction of antiserum CT1 with
both rhodopsin and B-adrenergic receptor. This is a relatively
short sequence to constitute an epitope. It was suggested that
immunological crossreactivity may be partly due to some
overall secondary/tertiary structural homology, perhaps re-
sponsible for positioning selected amino acid sequences for
interaction with other proteins such as G proteins or kinases,
interactions characteristic of all members of this receptor
family. The presence of the same 3 amino acids seems to be
important to CT1 reactivity with OBP also, although we
cannot rule out the possibility that the next 3 amino acids may
play a role as well, since they too were absent from the
control rhodopsin peptide (0-15) available to us.
It should be noted that the antigenic regions for CT1 under
consideration have nothing to do with the specificity of the G
protein bound, since each of the three crossreacting proteins
interacts with a different G protein (G, for rhodopsin, Gs for
the f8-adrenergic receptor, and one of several types of G,
and/or Go proteins for OBP).
The present data represent experimental support for the
hypothesis that At opioid receptors have the structure char-
acteristic of receptors that mediate signal transduction via G
proteins. The particular G protein through which As opioid
receptors produce their effects will have to be determined by
reconstitution of purified binding protein with purified G
proteins as well as by electrophysiological studies. The
cloning and complete sequencing ofthe binding protein ofthe
,u opioid receptor should confirm the presence of the seven
membrane-spanning domains typical of G-protein-coupled
receptors. It should also permit a detailed examination of the
various functional domains involved in the membrane, li-
gand, and G-protein interactions of opioid receptors.
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